However, combined with the previous reports that pre-treatment with Fpr2/3 agonists guards against neuroinflammatory damage [23,24,25], our finding that Fpr2/3 stimulation can reverse inflammatory microglial behaviours strongly suggests that Fpr2/3 agonists capable of dampening pathological microglial activity could hold therapeutic promise for numerous neurological diseases. The gene discussed is FPR2; the disease is nervous system disorder.